We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-1.02%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$10.5B
AUM Growth
-$388M
(-3.6%)
Cap. Flow
-$87.6M
Cap. Flow
% of AUM
-0.84%
Top 10 Holdings %
Top 10 Hldgs %
14.73%
Holding
713
New
186
Increased
183
Reduced
156
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSH
Marsh
MRSH
|
+$120M |
| 2 |
Chord Energy
CHRD
|
+$106M |
| 3 |
Electronic Arts
EA
|
+$96.9M |
| 4 |
Quest Diagnostics
DGX
|
+$89.2M |
| 5 |
Sensata Technologies
ST
|
+$76.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$138M |
| 2 |
Avnet
AVT
|
+$130M |
| 3 |
ERF
Enerplus Corporation
ERF
|
+$110M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$73.5M |
| 5 |
Honeywell
HON
|
+$72.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.43% |
| 2 | Technology | 19.78% |
| 3 | Energy | 7.84% |
| 4 | Industrials | 7.21% |
| 5 | Financials | 7.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Amcor
AMCR
$21.3B
| $8.24M | 0.08% |
+168,451
| New | +$8.17M |
|
277
Phathom Pharmaceuticals
PHAT
$726M
| $8.1M | 0.08% |
785,990
+219,551
| +39% | +$2.26M |
|
278
Cencora
COR
$60B
| $8.07M | 0.08% |
35,836
-69,402
| -66% | -$16.1M |
|
279
Curtiss-Wright
CW
$27.6B
| $7.97M | 0.08% |
29,415
-12,719
| -30% | -$3.4M |
|
280
Ryan Specialty Holdings
RYAN
$5.65B
| $7.96M | 0.08% |
+137,517
| New | +$7.34M |
|
281
AdaptHealth
AHCO
$1.47B
| $7.83M | 0.07% |
+782,913
| New | +$7.96M |
|
|
CPRX
282
DELISTED
Catalyst Pharmaceutical
CPRX
| $7.8M | 0.07% |
503,735
-23
| -0% | -$358 |
|
283
Broadcom
AVGO
$1.87T
| $7.79M | 0.07% |
48,500
-9,420
| -16% | -$1.32M |
|
|
SILK
284
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $7.73M | 0.07% |
+286,016
| New | +$5.95M |
|
285
Viking Holdings
VIK
$47.5B
| $7.64M | 0.07% |
+225,000
| New | +$6.79M |
|
286
Edgewise Therapeutics
EWTX
$4.13B
| $7.59M | 0.07% |
421,604
+16,472
| +4% | +$287K |
|
287
Mohawk Industries
MHK
$8.11B
| $7.48M | 0.07% |
65,815
-19,507
| -23% | -$2.27M |
|
288
Varonis Systems
VRNS
$4.73B
| $7.3M | 0.07% |
+152,143
| New | +$6.74M |
|
289
TD Synnex
SNX
$20.3B
| $7.29M | 0.07% |
63,139
-118,000
| -65% | -$14.4M |
|
|
VRNA
290
DELISTED
Verona Pharma
VRNA
| $7.25M | 0.07% |
501,198
-338,569
| -40% | -$4.94M |
|
|
DFTX
291
Definium Therapeutics
DFTX
$5.55B
| $7.22M | 0.07% |
1,001,250
+671
| +0.1% | +$5.87K |
|
|
APLS
292
DELISTED
Apellis Pharmaceuticals
APLS
| $7.17M | 0.07% |
187,000
+2
| +0% | +$91 |
|
293
Knight Transportation
KNX
$11.1B
| $7.03M | 0.07% |
+140,807
| New | +$6.89M |
|
294
XPO
XPO
$23.1B
| $7.02M | 0.07% |
66,116
-82,061
| -55% | -$9.2M |
|
295
Goodyear
GT
$2.02B
| $7M | 0.07% |
616,532
-52,078
| -8% | -$637K |
|
296
Organon & Co
OGN
$3.56B
| $6.97M | 0.07% |
336,829
-915,676
| -73% | -$18.2M |
|
297
Mirum Pharmaceuticals
MIRM
$6.38B
| $6.97M | 0.07% |
203,720
-29,547
| -13% | -$775K |
|
298
Regal Rexnord
RRX
$14.1B
| $6.95M | 0.07% |
+51,400
| New | +$8M |
|
|
299
Avnet
AVT
$7.29B
| $6.92M | 0.07% |
134,423
-2,546,963
| -95% | -$130M |
|
300
Carlisle Companies
CSL
$14.8B
| $6.9M | 0.07% |
+17,029
| New | +$6.86M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2024 Portfolio in Review
As of Q2 2024, Woodline Partners held 713 positions worth $10.5B, down 3.6% from $10.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners's Q2 2024 filing shows 186 new, 183 increased, 156 reduced and 168 closed positions. Its largest new stake was Marsh: 585,204 shares worth $123M. The largest sale was Analog Devices, an estimated $138M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Energy.
- Woodline Partners's largest Q2 2024 buy was Marsh: 585,204 shares worth $123M.
- Woodline Partners added most to Chord Energy in Q2 2024, an estimated $106M increase.
- Woodline Partners's biggest Q2 2024 reduction was Avnet, cutting an estimated $130M.
- Woodline Partners fully exited Analog Devices in Q2 2024, selling an estimated $138M.
- Woodline Partners's ten largest holdings make up 15% of its $10.5B portfolio in Q2 2024.
- Woodline Partners opened 186 new positions and closed 168 in Q2 2024.
- Woodline Partners's portfolio value fell 3.6% quarter-over-quarter to $10.5B.
Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.